Join
Live feed
·
INSIDERFilingvia Quantisnow
Travere Therapeutics Inc. logo

Chief Research Officer Rote William E. sold $355,719 worth of shares (9,100 units at $39.09) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 113,987 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TVTX· Travere Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.